Peter Thuss-Patience

Peter Thuss-Patience at Charite University Hospital has contributed to defining second-line treatment strategies for advanced gastric and GEJ cancer, including evaluation of ramucirumab plus paclitaxel. He has been active in the German AIO GI research network and has contributed to European gastric cancer clinical trials. His work on patient selection for second-line gastric cancer therapy and understanding prognostic factors after first-line failure has contributed to clinical decision-making. He has participated in evaluating multiple novel agents including VEGFR2 inhibitors, mTOR inhibitors, and checkpoint inhibitors in the relapsed gastric setting.